SHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026

Stock News

05/07

SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.

Analyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1173549406"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173549406\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173549406?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173549406","market":"hk","top_or_hot":-1,"title":"SHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026","media":"Stock News","content":"<p>SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.</p>\n<p>Analyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-05-07 17:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.</p>\n<p>Analyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1173549406","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173549406","pubTimestamp":1778145618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1606":"中医药概念","02877":"神威药业"},"translate_title":"神威药业报告2026年第一季度收入下降18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02877":1},"content_text":"SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.\nAnalyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}